Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy
Percutaneous revascularisation has evolved dramatically in the past few decades. The approach to the management of ischaemic heart disease has changed due to the development of new devices and techniques as well as the availability of new drugs and treatment strategies. Its use in combination with a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2020-02-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2019.25.2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104675538305024 |
|---|---|
| author | Tamara García Camarero José M de la Torre Hernández |
| author_facet | Tamara García Camarero José M de la Torre Hernández |
| author_sort | Tamara García Camarero |
| collection | DOAJ |
| description | Percutaneous revascularisation has evolved dramatically in the past few decades. The approach to the management of ischaemic heart disease has changed due to the development of new devices and techniques as well as the availability of new drugs and treatment strategies. Its use in combination with antiplatelet therapies has been essential to protect against stent thrombosis. The length of time this combination therapy is used has been modified in recent years and has been the subject of extensive research. The effect of prolonging the time it is taken or shortening it has been evaluated in different clinical conditions. In practice, the decisions regarding antithrombotic therapy after percutaneous coronary intervention are informed by the patient’s profile and the characteristics of the procedures performed. In this article, we review the use of antiplatelet/anticoagulant therapy after percutaneous coronary intervention focusing on trials and guidelines addressing variable durations for combination regimens and the alternatives. |
| format | Article |
| id | doaj-art-ee6142e66f9d4614b35c8e41a8d1ecd8 |
| institution | DOAJ |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2020-02-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-ee6142e66f9d4614b35c8e41a8d1ecd82025-08-20T02:39:16ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642020-02-011510.15420/ecr.2019.25.2Antithrombotic Treatment After Coronary Intervention: Agreement and ControversyTamara García Camarero0José M de la Torre Hernández1Department of Interventional Cardiology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, SpainDepartment of Interventional Cardiology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, SpainPercutaneous revascularisation has evolved dramatically in the past few decades. The approach to the management of ischaemic heart disease has changed due to the development of new devices and techniques as well as the availability of new drugs and treatment strategies. Its use in combination with antiplatelet therapies has been essential to protect against stent thrombosis. The length of time this combination therapy is used has been modified in recent years and has been the subject of extensive research. The effect of prolonging the time it is taken or shortening it has been evaluated in different clinical conditions. In practice, the decisions regarding antithrombotic therapy after percutaneous coronary intervention are informed by the patient’s profile and the characteristics of the procedures performed. In this article, we review the use of antiplatelet/anticoagulant therapy after percutaneous coronary intervention focusing on trials and guidelines addressing variable durations for combination regimens and the alternatives.https://www.ecrjournal.com/articleindex/ecr.2019.25.2 |
| spellingShingle | Tamara García Camarero José M de la Torre Hernández Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy European Cardiology Review |
| title | Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy |
| title_full | Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy |
| title_fullStr | Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy |
| title_full_unstemmed | Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy |
| title_short | Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy |
| title_sort | antithrombotic treatment after coronary intervention agreement and controversy |
| url | https://www.ecrjournal.com/articleindex/ecr.2019.25.2 |
| work_keys_str_mv | AT tamaragarciacamarero antithrombotictreatmentaftercoronaryinterventionagreementandcontroversy AT josemdelatorrehernandez antithrombotictreatmentaftercoronaryinterventionagreementandcontroversy |